- Home
- STSS vs VRAX Comparison
STSS vs VRAX Comparison
Compare STSS & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- VRAX
- Stock Information
- Founded
- STSS 2017
- VRAX 2013
- Country
- STSS United States
- VRAX United Kingdom
- Employees
- STSS N/A
- VRAX N/A
- Industry
- STSS Medical/Dental Instruments
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- STSS Health Care
- VRAX Health Care
- Exchange
- STSS Nasdaq
- VRAX Nasdaq
- Market Cap
- STSS 5.1M
- VRAX 4.4M
- IPO Year
- STSS 2022
- VRAX 2022
- Fundamental
- Price
- STSS $7.36
- VRAX $0.77
- Analyst Decision
- STSS
- VRAX Strong Buy
- Analyst Count
- STSS 0
- VRAX 1
- Target Price
- STSS N/A
- VRAX $3.00
- AVG Volume (30 Days)
- STSS 90.2K
- VRAX 79.3K
- Earning Date
- STSS 08-13-2025
- VRAX 01-01-0001
- Dividend Yield
- STSS N/A
- VRAX N/A
- EPS Growth
- STSS N/A
- VRAX N/A
- EPS
- STSS N/A
- VRAX N/A
- Revenue
- STSS $222,722.00
- VRAX $6,331.00
- Revenue This Year
- STSS N/A
- VRAX $217,274.83
- Revenue Next Year
- STSS N/A
- VRAX N/A
- P/E Ratio
- STSS N/A
- VRAX N/A
- Revenue Growth
- STSS N/A
- VRAX N/A
- 52 Week Low
- STSS $3.36
- VRAX $0.72
- 52 Week High
- STSS $2,145.00
- VRAX $7.63
- Technical
- Relative Strength Index (RSI)
- STSS 67.00
- VRAX 41.98
- Support Level
- STSS $4.54
- VRAX $0.74
- Resistance Level
- STSS $5.95
- VRAX $0.80
- Average True Range (ATR)
- STSS 0.74
- VRAX 0.05
- MACD
- STSS 0.18
- VRAX -0.00
- Stochastic Oscillator
- STSS 96.92
- VRAX 33.59
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).